In context of the improved response to chemotherapy in combination with attenuated GH action in our earlier in vitro and current in vivo studies in melanoma, we further hypothesized that other cancer types with GHR expression may also be amenable to this therapy sensitizing effects. The gene discussed is GH1; the disease is cancer.